GSK's Trelegy Ellipta (Fluticasone Furoate/Umeclidinium/Vilanterol ‘FF/UMEC/VI') Receives Expanded Level Approval from EU for COPD
Shots:
- The IMPACT study involves assessing of Trelegy Ellipta (qd-100/62.5/25mcg) vs (ICS/LABA Relvar/Breo Ellipta (FF/VI)) (100/25mcg) & ((LAMA)/LABA Anoro Ellipta (UMEC/VI)) (62.5/25mcg) in patients with COPD
- The Expanded label approval will serve as a maintenance treatment for patients with moderate-to-severe COPD and shown effective results in comparison to ICS- LABA & LAMA. In 2017- Trelegy Ellipta has also received EU approval for this indication
- Trelegy Ellipta is a novel triple therapy inhaler- with combination of three molecules and is approved in US for airflow obstruction in patients with COPD- including chronic bronchitis and emphysema
Ref: GSK | Image: GSK
Click here to read the full press release
Tags
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com